GW Pharmaceuticals plc, of London, said the FDA granted fast track designation for an intravenous form of cannabidiol (CBD) to treat neonatal hypoxic-ischemic encephalopathy, or NHIE. The EMA, meanwhile, granted orphan designation for the drug in perinatal asphyxia, a term that also describes NHIE.